93 Research Achievements of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences Were Showcased at the 66th ASH

93 Research Achievements of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences Were Showcased at the 66th ASH

The 66th Annual Meeting of the American Society of Hematology (ASH), the largest global academic event in the field of hematology, took place from December 7 to 10, 2024, in San Diego, USA. The event brought  together leading researchers and clinicians from around the world to discuss cutting-edge advancements in hematology, innovative therapies, and ongoing clinical trials.Following rigorous peer review, 10 high-quality abstracts from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences were selected for oral presentations, and an additional 83 abstracts were featured in poster sessions.
JITC丨Combination of Autologous Transplantation and CAR-T Cells Enhances Outcomes in Refractory Large B-Cell Lymphoma: Findings from the Team of Professor Dehui Zou and Professor WentingZheng

JITC丨Combination of Autologous Transplantation and CAR-T Cells Enhances Outcomes in Refractory Large B-Cell Lymphoma: Findings from the Team of Professor Dehui Zou and Professor WentingZheng

Chimeric antigen receptor T-cell (CAR-T) therapy is one of the most promising salvage treatments for relapsed/refractory large B-cell lymphoma (r/r LBCL), offering durable remission for about one-third of patients. However, the remaining two-thirds either fail to respond to CAR-T therapy or experience relapse, resulting in poor survival outcomes. This underscores the urgent need to explore methods to enhance the efficacy of CAR-T therapy.
2025 CASH丨Dr. Rong Fu: Interpretation of the PNH China Guidelines

2025 CASH丨Dr. Rong Fu: Interpretation of the PNH China Guidelines

The 5th Annual Meeting of Chinese Alliance for Societies of Hematology (2025 CASH) was held in Tianjin from January 3 to 5, under the theme “Comprehensive Hematology, Comprehensive Health, and Comprehensive Well-being.” Top hematology experts from China and abroad were invited to discuss the latest advancements and future trends in hematology.
Annual Review | Prof. Shuhua Yi: Highlights of 2024 Advances in Mantle Cell Lymphoma

Annual Review | Prof. Shuhua Yi: Highlights of 2024 Advances in Mantle Cell Lymphoma

In recent years, the field of hematologic oncology has experienced remarkable breakthroughs, with significant advancements in mantle cell lymphoma (MCL). Chinese researchers have increasingly contributed to this progress, playing a pivotal role in driving academic development and clinical practice in the field. As we step into the new year, Hematology Frontier invited Professor Shuhua Yi from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, to review the major events and breakthroughs in MCL during 2024. This comprehensive summary aims to provide valuable insights for clinical practice and future research directions.